Gilead Sciences Acquires Repare’s RP-3467 to Expand Precision Oncology Pipeline

Gilead Sciences (NASDAQ: GILD) has agreed to acquire RP-3467, an investigational cancer therapy developed by Repare Therapeutics (NASDAQ: RPTX), in a transaction valued at up to $30 million. The deal adds a novel DNA-repair–targeting asset to Gilead’s oncology portfolio and reflects its continued focus on precision medicine.

Under the agreement, Repare will receive $25 million upfront, with the potential for an additional $5 million tied to the successful completion of specified technology-transfer milestones. Following the transaction, Gilead will assume responsibility for further development of the compound.

Targeting DNA Repair Pathways in Cancer

RP-3467 is a small-molecule inhibitor of polymerase theta (Polθ), a DNA repair enzyme that plays a key role in an error-prone repair pathway used by certain cancer cells. Tumors with defects in other DNA repair mechanisms—such as those involving BRCA mutations—may rely more heavily on Polθ for survival, making it an attractive therapeutic target.

By inhibiting Polθ, RP-3467 is designed to exploit synthetic lethality, selectively damaging cancer cells while sparing healthy tissue. This approach aligns with growing interest in targeted therapies that address the underlying genetic vulnerabilities of tumors.

Clinical Development Underway

The compound is currently being evaluated in the POLAR Phase 1 clinical trial, where it is being studied both as a monotherapy and in combination with the PARP inhibitor olaparib. The trial is assessing safety, tolerability, and early signals of activity in patients with advanced solid tumors, including ovarian, breast, prostate, and pancreatic cancers.

Strategic Impact for Both Companies

For Gilead, the acquisition strengthens its precision oncology pipeline with a differentiated mechanism that complements existing programs focused on genomic instability and targeted cancer treatments.

For Repare, the transaction provides near-term capital and further validates its DNA damage response platform. The upfront payment is expected to enhance Repare’s cash position and may increase shareholder value in connection with its previously announced strategic transactions.

Broader Context

Interest in DNA repair–targeting therapies continues to grow as researchers seek more effective and selective cancer treatments. Gilead’s acquisition of RP-3467 highlights ongoing consolidation in oncology development and underscores the strategic value of assets that address specific genetic drivers of disease.